| Basics |
Solid Biosciences Inc.
Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.
|
| IPO Date: |
January 26, 2018 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$428.28M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.33 | 4.00%
|
| Avg Daily Range (30 D): |
$0.16 | 2.67%
|
| Avg Daily Range (90 D): |
$0.19 | 4.21%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.73M |
| Avg Daily Volume (30 D): |
.88M |
| Avg Daily Volume (90 D): |
1.3M |
| Trade Size |
| Avg Trade Size (Sh.): |
158 |
| Avg Trade Size (Sh.) (30 D): |
94 |
| Avg Trade Size (Sh.) (90 D): |
117 |
| Institutional Trades |
| Total Inst.Trades: |
366 |
| Avg Inst. Trade: |
$1.63M |
| Avg Inst. Trade (30 D): |
$.77M |
| Avg Inst. Trade (90 D): |
$1.4M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.12M |
| Avg Closing Trade (30 D): |
$.8M |
| Avg Closing Trade (90 D): |
$1.59M |
| Avg Closing Volume: |
162.01K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-2.82
|
$-.42
|
$-.59
|
|
Diluted EPS
|
$-2.65
|
$-.42
|
$-.42
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -154.08M
|
$ -39.48M
|
$ -39.28M
|
|
Operating Income / Loss
|
$ -156.82M
|
$ -41.69M
|
$ -40.05M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 43.09M
|
$ -71.75M
|
$ 130.42M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 28, 2022:
1:15
|
|
|
|
